





May 18, 2022

Company: FINDEX Inc

Representative: Teruo Aibara, President & CEO

(Stock code: 3649, TSE Prime)

Contact: Atsushi Fujita

Director and Head of Administration

(TEL: +81-89-947-3388)

Notice Regarding the Revision of the Financial Forecast for the Second Quarter of the Fiscal Year Ending December 31, 2022 (Consolidated, Non-consolidated)

This is to announce that FINDEX Inc. hereby upwardly revises the financial forecasts, both on consolidated and non-consolidated basis, for the second quarter of the fiscal year ending December 31, 2022, which was released on February 9, 2022.

1. Revision of Consolidated Financial Forecast (From January 1, 2022, to June 30, 2022)

1. Revision of Consolidated I manetal I ofecast (1 form sandary 1, 2022; to same 50, 2022)								
	Revenue	Operating income	Ordinary income	Net income attributable owners of the parent company	Basic earnings per share			
	(JPY MM)	(JPY MM)	(JPY MM)	(JPY MM)	(JPY)			
Previously announced forecast (A)	1,953	136	137	82	3.20			
Revised forecast (B)	2,253	404	415	273	10.66			
Variance in amount (B-A)	300	268	278	191	-			
Variance in percentage (%)	15.4	197.1	202.9	232.9	-			
(Ref.) Actual results for FY2021 2Q (Cumulative, from Jan. 1, 2021, to Jun.31, 2021)	2,405	488	505	340	13.30			

2. Revision of Non-Consolidated Financial Forecast (From January 1, 2022, to June 30, 2022)

	Revenue	Ordinary income	Net income	Basic earnings per share
	(JPY MM)	(JPY MM)	(JPY MM)	(JPY)
Previously announced forecast (A)	1,892	160	111	4.33
Revised forecast (B)	2,205	436	302	11.79
Variance in amount (B-A)	313	276	191	-
Variance in percentage (%)	16.5	172.5	172.1	-
(Ref.) Actual results for FY2021 2Q (Cumulative, from Jan. 1, 2021, to Jun.31, 2021)	2,390	521	362	14.14

3. Reason for the Revision of Financial Forecast Above

Revenue for the second quarter of the fiscal year ending December 31, 2022, is expected to exceed the forecasted amounts which were predicted at the beginning of current fiscal year, mainly due to the additional winning of both direct and indirect sales in medical information system development segment, and the ahead-of-schedule implementations from the third quarter and beyond.

In accordance with the incremental revenue above, each line of income is also expected to exceed the forecasted amount, respectively.

Although the forecasted amounts for the full year remain unchanged, should there be any changes expected in our business performance, we will immediately announce such situations.

The forecasted amounts included in this document have been predicted and calculated based on information available for us at the time of this announcement. Due consideration should be given that actual figures might differ due to various factors.